-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RmXWa+MDEKbf0Wfleuhhkc1cu+oGEquazc90OyRUqKSqw7NOSSfLP5Euk0iUMMbm jVP7t2w63YZbOj/Uil5Fag== 0000898432-09-000125.txt : 20090130 0000898432-09-000125.hdr.sgml : 20090130 20090130161457 ACCESSION NUMBER: 0000898432-09-000125 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090130 DATE AS OF CHANGE: 20090130 GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND II, L.P. GROUP MEMBERS: BVF INC. GROUP MEMBERS: BVF INVESTMENTS, L.L.C. GROUP MEMBERS: BVF PARTNERS L.P. GROUP MEMBERS: INVESTMENT 10, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-38071 FILM NUMBER: 09558495 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 BUSINESS PHONE: 3125066500 MAIL ADDRESS: STREET 1: 900 N. MICHIGAN AVENUE, SUITE 1100 CITY: CHICAGO STATE: IL ZIP: 60611 SC 13G/A 1 bvf_repligen13g-a.htm

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
     

SCHEDULE 13G
(Rule 13d-102)
          

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
     
     (Amendment No. 4)*
     

Repligen Corporation

(Name of Issuer)
 

Common Stock

(Title of Class of Securities)

759916109

(CUSIP Number)

December 31, 2008

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o

Rule 13d-1(b)

x

 Rule 13d-1(c)

o

 Rule 13d-1(d)
   

     

     

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
          

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

         

CUSIP No. 759916109

  

13G

  

Page 2 of 10 Pages
 

1

  

NAME OF REPORTING PERSON:
Biotechnology Value Fund, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a) x
       

(b) o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION


   
Delaware

   

5

  

SOLE VOTING POWER

NUMBER OF

      

0

SHARES

    

BENEFICIALLY

  

6

  

SHARED VOTING POWER

OWNED

      

667,150

BY

    

EACH

  

7

  

SOLE DISPOSITIVE POWER

REPORTING

      

0

PERSON

    

WITH:

  

8

  

SHARED DISPOSITIVE POWER
       

667,150
 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


   
667,150

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

o





 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


   
2.14%

 

12

  

TYPE OF REPORTING PERSON*

    
 

PN

    


         

CUSIP No. 759916109

  

13G

  

Page 3 of 10 Pages

1

  

NAME OF REPORTING PERSON:
Biotechnology Value Fund II, L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a) x
       

(b) o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION

    


     
Delaware


   

5

  

SOLE VOTING POWER

NUMBER OF

      

0

SHARES

    

BENEFICIALLY

  

6

  

SHARED VOTING POWER

OWNED

      

425,400

BY

    

EACH

  

7

  

SOLE DISPOSITIVE POWER

REPORTING

      

0

PERSON

    

WITH:

  

8

  

SHARED DISPOSITIVE POWER
       

425,400
 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


     
425,400

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

o





 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


     
1.36%

 

12

  

TYPE OF REPORTING PERSON*

    
 

     
PN

    
         


         

CUSIP No. 759916109

  

13G

  

Page 4 of 10 Pages
         
 

1

  

NAME OF REPORTING PERSON:
BVF Investments, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a) x
       

(b) o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION

    


   
Delaware

 
   

5  

  SOLE VOTING POWER

NUMBER OF

    

0

SHARES

    

BENEFICIALLY

  

6  

  SHARED VOTING POWER

OWNED

      1,476,700

BY

    

EACH

  

7  

SOLE DISPOSITIVE POWER

REPORTING

    

0

PERSON

    

WITH:

  

8  

SHARED DISPOSITIVE POWER
     

1,476,700

 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


   
1,476,700

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

o



 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


    
4.74%

 

12

  

TYPE OF REPORTING PERSON*

    


    
OO

 


         

CUSIP No. 759916109

  

13G

  

Page 5 of 10 Pages

 

1

  

NAME OF REPORTING PERSON:
Investment 10, L.L.C.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a)  x
       

(b)  o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION

    


   
Illinois


   

5

  

SOLE VOTING POWER

NUMBER OF

      

0

SHARES

    

BENEFICIALLY

  

6

  

SHARED VOTING POWER

OWNED

      

162,100

BY

    

EACH

  

7

  

SOLE DISPOSITIVE POWER

REPORTING

      

0

PERSON

    

WITH:

  

8

  

SHARED DISPOSITIVE POWER
       

162,100
 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


   
162,100

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

o




 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


   
0.52%

 

12

  

TYPE OF REPORTING PERSON*

    


   
OO

 

         

CUSIP No. 759916109

  

13G

  

Page 6 of 10 Pages

1

  

NAME OF REPORTING PERSON:
BVF Partners L.P.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a)  x
       

(b)  o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION

    


   
Delaware


   

5

  

SOLE VOTING POWER

NUMBER OF

      

0

SHARES

    

BENEFICIALLY

  

6

  

SHARED VOTING POWER

OWNED

      

2,731,350

BY

    

EACH

  

7

  

SOLE DISPOSITIVE POWER

REPORTING

      

0

PERSON

    

WITH:

  

8

  

SHARED DISPOSITIVE POWER
       

2,731,350
 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


   
2,731,350

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

o





 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


     
8.76%

 

12

  

TYPE OF REPORTING PERSON*

    


     
PN

 


       

 

CUSIP No. 759916109

  

13G

  

Page 7 of 10 Pages
   

1

  

NAME OF REPORTING PERSON:
BVF Inc.
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

    
 

2

  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

  

(a)  x
       

(b)  o
         
 

3

  

SEC USE ONLY

    





 

4

  

CITIZENSHIP OR PLACE OF ORGANIZATION

    


   
Delaware

 
   

5

  

SOLE VOTING POWER

NUMBER OF

      

0

SHARES

    

BENEFICIALLY

  

6

  

SHARED VOTING POWER

OWNED

      

2,731,350

BY

    

EACH

  

7

  

SOLE DISPOSITIVE POWER

REPORTING

      

0

PERSON

    

WITH:

  

8

  

SHARED DISPOSITIVE POWER
       

2,731,350
 

9

  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    


   
2,731,350

 

10

  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

  

 

o





 

11

  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    


   
8.76%

 

12

  

TYPE OF REPORTING PERSON*

    


   
IA, CO

 

         

CUSIP No. 759916109

  

13G

  

Page 8 of 10 Pages


ITEM 1(a).      NAME OF ISSUER:

Repligen Corporation (“RGEN”)
    

ITEM 1(b).      ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
    

41 Seyon Street Building 1, Suite 100

Waltham, Massachusetts 02453
    

ITEM 2(a).      NAME OF PERSON FILING:
    

This Amendment No. 4 to Schedule 13G is being filed on behalf of the following persons (the “Reporting Persons”):     

 

(i)

  

Biotechnology Value Fund, L.P. (“BVF”)
 

(ii)

  

Biotechnology Value Fund II, L.P. (“BVF2”)
 

(iii)

  

BVF Investments, L.L.C. (“Investments”)
 

(iv)

  

Investment 10, L.L.C. (“ILL10”)
 

(v)

  

BVF Partners L.P. (“Partners”)
 

(vi)

  

BVF Inc. (“BVF Inc.”)

ITEM 2(b).      ADDRESS OF PRINCIPAL BUSINESS OFFICE:
    

The principal business office of the Reporting Persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.
    

ITEM 2(c).      CITIZENSHIP:

   

BVF:

a Delaware limited partnership
   

BVF2:

a Delaware limited partnership
   

Investments:

a Delaware limited liability company
   

ILL10:

an Illinois limited liability company
   

Partners:

a Delaware limited partnership
   

BVF Inc.:

a Delaware corporation
   

ITEM 2(d).      TITLE OF CLASS OF SECURITIES:
    

This Amendment No. 4 to Schedule 13G is being filed with respect to the common stock, par value $0.01 per share (“Common Stock”), of RGEN. The Reporting Persons’ percentage ownership of Common Stock is based on 31,184,534 shares of Common Stock being outstanding.
     

As of December 31, 2008, BVF beneficially owned 667,150 shares of Common Stock, BVF2 beneficially owned 425,400 shares of Common Stock, Investments beneficially owned 1,476,700 shares of Common Stock and ILL10 beneficially owned 162,100 shares of Common Stock. Beneficial ownership by Partners and BVF Inc. includes 2,731,350 shares of Common Stock.
    

         

CUSIP No. 759916109

  

13G

  

Page 9 of 10 Pages
      

ITEM 2(e).      CUSIP Number: 759916109
    

ITEM 3.        IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS:    One of the following
    

Not applicable as this Amendment No. 4 to Schedule 13G is filed pursuant to Rule 13d-1(c).
    

ITEM 4.        OWNERSHIP:
    

The information in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Amendment No. 4 to Schedule 13G is hereby incorporated by reference.
    

ITEM 5.        OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities check the following.  [ ].

ITEM 6.        OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Samana Capital, L.P., the majority member of Investments, in shares of the Common Stock beneficially owned by Investments and to vote and exercise dispositive power over those shares of the Common Stock. Partners and BVF Inc. share voting and dispositive power over shares of the Common Stock beneficially owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners acts as an investment manager and, accordingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common Stock owned by such parties.
    

ITEM 7.        IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: 
   

Mr. Lampert is the owner, sole director and an officer of BVF Inc. BVF Inc. is the general partner of Partners, which is the general partner of BVF and BVF 2. Partners is the manager of Investments and is investment adviser to ILL10.
    

ITEM 8.        IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:
    

The members of the group making this filing of Amendment No. 4 to Schedule 13G are: Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., Investment 10, L.L.C., BVF Partners L.P. and BVF Inc.
    

ITEM 9.        NOTICE OF DISSOLUTION OF GROUP:
    

Not applicable.



         

CUSIP No. 759916109

  

13G

  

Page 10 of 10 Pages
    

ITEM 10.        CERTIFICATION
    

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    

Dated: January 30, 2009


    

BIOTECHNOLOGY VALUE FUND, L.P.*

By: BVF Partners, L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

BIOTECHNOLOGY VALUE FUND II, L.P.*

By: BVF Partners, L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

BVF INVESTMENTS, L.L.C.*

By: BVF Partners, L.P., its manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

INVESTMENT 10, L.L.C.*

By: BVF Partners, L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

BVF PARTNERS L.P.*

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

BVF INC.*

By: /s/ Mark N. Lampert_________

Mark N. Lampert, President

*The Reporting Person disclaims beneficial ownership except to the extent of its pecuniary interest therein.

 

 

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Amendment No. 4 to Schedule 13G, dated December 31, 2008, relating to the Common Stock of RGEN shall be filed on behalf of the undersigned.

Dated: January 30, 2009

BIOTECHNOLOGY VALUE FUND, L.P.*

By: BVF Partners, L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert                      

Mark N. Lampert, President

BIOTECHNOLOGY VALUE FUND II, L.P.*

By: BVF Partners, L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert                      

Mark N. Lampert, President

BVF INVESTMENTS, L.L.C.*

By: BVF Partners, L.P., its manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert                      

Mark N. Lampert, President

INVESTMENT 10, L.L.C.*

By: BVF Partners, L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert                     

Mark N. Lampert, President

BVF PARTNERS L.P.*

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert                     

Mark N. Lampert, President

BVF INC.*

By: /s/ Mark N. Lampert                      

Mark N. Lampert, President

 -----END PRIVACY-ENHANCED MESSAGE-----